- Home
- MRNS vs DERM Comparison
MRNS vs DERM Comparison
Compare MRNS & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRNS
- DERM
- Stock Information
- Founded
- MRNS 2003
- DERM 2014
- Country
- MRNS United States
- DERM United States
- Employees
- MRNS N/A
- DERM N/A
- Industry
- MRNS Biotechnology: Pharmaceutical Preparations
- DERM Biotechnology: Pharmaceutical Preparations
- Sector
- MRNS Health Care
- DERM Health Care
- Exchange
- MRNS Nasdaq
- DERM Nasdaq
- Market Cap
- MRNS 76.0M
- DERM 97.0M
- IPO Year
- MRNS 2014
- DERM 2021
- Fundamental
- Price
- MRNS $1.40
- DERM $4.68
- Analyst Decision
- MRNS Buy
- DERM Strong Buy
- Analyst Count
- MRNS 6
- DERM 3
- Target Price
- MRNS $10.50
- DERM $9.50
- AVG Volume (30 Days)
- MRNS 322.2K
- DERM 57.2K
- Earning Date
- MRNS 11-05-2024
- DERM 08-12-2024
- Dividend Yield
- MRNS N/A
- DERM N/A
- EPS Growth
- MRNS N/A
- DERM N/A
- EPS
- MRNS N/A
- DERM 0.04
- Revenue
- MRNS $30,263,000.00
- DERM $77,681,000.00
- Revenue This Year
- MRNS $20.42
- DERM N/A
- Revenue Next Year
- MRNS $57.03
- DERM $52.21
- P/E Ratio
- MRNS N/A
- DERM $106.69
- Revenue Growth
- MRNS 16.56
- DERM 26.38
- 52 Week Low
- MRNS $1.05
- DERM $2.33
- 52 Week High
- MRNS $11.26
- DERM $8.11
- Technical
- Relative Strength Index (RSI)
- MRNS 53.94
- DERM 44.40
- Support Level
- MRNS $1.35
- DERM $4.84
- Resistance Level
- MRNS $1.53
- DERM $5.33
- Average True Range (ATR)
- MRNS 0.09
- DERM 0.30
- MACD
- MRNS 0.01
- DERM 0.01
- Stochastic Oscillator
- MRNS 53.57
- DERM 34.91
About MRNS Marinus Pharmaceuticals Inc.
Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.